Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, ...

"Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...

Learn more about whether Ligand Pharmaceuticals Incorporated or Viatris Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

For now, however, the Prevnar brand remains largely unscathed ... "Despite the availability of current pneumococcal conjugate vaccines, many adults remain vulnerable to pneumococcal disease ...

Second, in the vaccine space, Pfizer's Prevnar franchise ... atirmociclib for breast cancer, and PCV-25 for pneumococcal disease, to name a few), and I think their top-line addition will be ...

This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine (PCV) in healthy infants. Adding to this headwind, the broader ...

In the past month, PCVX's shares have nosedived 56%. This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine (PCV) in ...

Given the uncertain regulatory environment, I am downgrading Vaxcyte's stock to "Hold" until there's more clarity on the FDA's stance on PCV vaccines. Phase 2 dose-finding study evaluating the ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...